|
Volumn 5, Issue 4, 2004, Pages 174-175
|
SSRIs: Are the accusations justified?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIDEPRESSANT AGENT;
BENZODIAZEPINE DERIVATIVE;
FLUOXETINE;
PAROXETINE;
PLACEBO;
SEROTONIN UPTAKE INHIBITOR;
CHILD PSYCHIATRY;
DATA ANALYSIS;
DEPRESSION;
DISEASE ASSOCIATION;
DRUG INDICATION;
DRUG INFORMATION;
DRUG MECHANISM;
DRUG UTILIZATION;
EDITORIAL;
EUROPE;
FOOD AND DRUG ADMINISTRATION;
HEALTH PRACTITIONER;
HUMAN;
INFORMATION DISSEMINATION;
INTERPERSONAL COMMUNICATION;
LICENCE;
MASS MEDIUM;
MEDICAL SPECIALIST;
PARADOXICAL DRUG REACTION;
REGISTRATION;
RESTLESSNESS;
RISK BENEFIT ANALYSIS;
SEDATION;
STATISTICAL ANALYSIS;
SUICIDAL BEHAVIOR;
TREATMENT OUTCOME;
UNITED STATES;
MAJOR DEPRESSION;
METHODOLOGY;
PSYCHOLOGICAL ASPECT;
SUICIDE;
ADOLESCENT PSYCHIATRY;
CHILD PSYCHIATRY;
DEPRESSIVE DISORDER, MAJOR;
FLUOXETINE;
HUMANS;
SEROTONIN UPTAKE INHIBITORS;
SUICIDE;
|
EID: 16644366009
PISSN: 15622975
EISSN: 18141412
Source Type: Journal
DOI: 10.1080/15622970410029932 Document Type: Editorial |
Times cited : (6)
|
References (6)
|